Reuters logo
22 days ago
BRIEF- Sumitomo Dainippon Pharma unit Sunovion announces FDA acceptance for review of new drug application resubmission for SUN-101
July 3, 2017 / 3:26 AM / 22 days ago

BRIEF- Sumitomo Dainippon Pharma unit Sunovion announces FDA acceptance for review of new drug application resubmission for SUN-101

1 Min Read

July 3(Reuters) - Sumitomo Dainippon Pharma Co Ltd

* Says its U.S.-based unit Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application for SUN-101/eFlow® (glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)

Source text in Japanese:goo.gl/peihA7

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below